Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma

NCT02506153 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT02506153
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02506153 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 3
Overall status
Active, not recruiting
Start date
November 10, 2015
Completion date
January 23, 2027
Enrollment
1,301 (actual)
Sites
576

Conditions

As the registry lists them; a condition with its own page is linked.

clinical stage iii cutaneous melanoma ajcc v8, clinical stage iv cutaneous melanoma ajcc v8, metastatic cutaneous melanoma, metastatic mucosal melanoma, metastatic non-cutaneous melanoma, non-cutaneous melanoma, recurrent cutaneous melanoma, recurrent mucosal melanoma, recurrent non-cutaneous melanoma